In its quest to bring ALS drug to mar­ket, Clene will ex­pand man­u­fac­tur­ing in Mary­land

As Utah-based Clene Nanomed­i­cine works to­ward ad­vanc­ing its ALS drug made from gold nanocrys­tals, it will soon do so with near­ly four times the man­u­fac­tur­ing ca­pac­i­ty.

Clene will quadru­ple its man­u­fac­tur­ing ca­pac­i­ty for lead drug CNM-Au8 at two dif­fer­ent man­u­fac­tur­ing sites in Mary­land, the com­pa­ny an­nounced Wednes­day. The ex­pan­sions in­clude ad­di­tion­al  R&D space, too, and set the com­pa­ny up to fur­ther its ef­forts in mul­ti­ple scle­ro­sis and Parkin­son’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER